These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

404 related articles for article (PubMed ID: 31305271)

  • 21. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database.
    Singla N; Hutchinson RC; Ghandour RA; Freifeld Y; Fang D; Sagalowsky AI; Lotan Y; Bagrodia A; Margulis V; Hammers HJ; Woldu SL
    Urol Oncol; 2020 Jun; 38(6):604.e9-604.e17. PubMed ID: 32253116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncologic Outcomes of Cytoreductive Nephrectomy in Synchronous Metastatic Renal-Cell Carcinoma: A Single-Center Experience.
    Choi CI; Kang M; Sung HH; Jeon HG; Jeong BC; Jeon SS; Lee HM; Seo SIL
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1189-e1199. PubMed ID: 30262447
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach.
    Hall ME; Bhindi B; Luckenbaugh AN; Laviana AA; Moses KA; Satkunasivam R; Rini B; Klaassen Z; Wallis CJD
    Cancer Causes Control; 2021 Jul; 32(7):675-680. PubMed ID: 33963938
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytoreductive nephrectomy for metastatic renal cell carcinoma.
    Chery LJ; Karam JA; Wood CG
    Clin Adv Hematol Oncol; 2016 Sep; 14(9):696-703. PubMed ID: 27673288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Position of cytoreductive nephrectomy in the setting of metastatic renal cell carcinoma patients: does the CARMENA trial lead to a paradigm shift?
    Dariane C; Timsit MO; Méjean A
    Bull Cancer; 2018 Dec; 105 Suppl 3():S229-S234. PubMed ID: 30595151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. TARIBO trial: targeted therapy with or without nephrectomy in metastatic renal cell carcinoma: liquid biopsy for biomarkers discovery.
    Verzoni E; Ratta R; Grassi P; Salvioni R; Stagni S; Montone R; Fucà G; Cappelletti V; Reduzzi C; De Giorgi U; Procopio G
    Tumori; 2018 Oct; 104(5):401-405. PubMed ID: 29192741
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: A Systematic Review With a Meta-Analysis.
    Petrelli F; Coinu A; Vavassori I; Cabiddu M; Borgonovo K; Ghilardi M; Lonati V; Barni S
    Clin Genitourin Cancer; 2016 Dec; 14(6):465-472. PubMed ID: 27138461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of cytoreductive nephrectomy combined with targeted therapy for metastatic renal cell carcinoma: a meta-analysis.
    Hong X; Li F; Tang K; Pang S; Lin G; Li S; Bao J; Tan W
    Int Urol Nephrol; 2016 Jun; 48(6):967-75. PubMed ID: 26861063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma in the era of targeted therapy: a bibliographic review.
    Faba OR; Brookman-May SD; Linares E; Breda A; Pisano F; Subiela JD; Sanguedolce F; Brausi M; Palou J
    World J Urol; 2017 Dec; 35(12):1807-1816. PubMed ID: 28702843
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytoreductive nephrectomy with thrombectomy before targeted therapy improves survival for metastatic renal cell carcinoma with venous tumor thrombus: a single-center experience.
    Qi N; Wu P; Chen J; Li T; Ning X; Wang J; Gong K
    World J Surg Oncol; 2017 Jan; 15(1):4. PubMed ID: 28056988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study.
    Woldu SL; Matulay JT; Clinton TN; Singla N; Freifeld Y; Sanli O; Krabbe LM; Hutchinson RC; Lotan Y; Hammers H; Hannan R; Brugarolas J; Bagrodia A; Margulis V
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1221-e1235. PubMed ID: 30217763
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
    Pal SK; Nelson RA; Vogelzang N
    PLoS One; 2013; 8(5):e63341. PubMed ID: 23658823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytoreductive Nephrectomy in the Era of Tyrosine Kinase and Immuno-Oncology Checkpoint Inhibitors.
    Biles MJ; Patel HD; Allaf ME
    Urol Clin North Am; 2020 Aug; 47(3):359-370. PubMed ID: 32600537
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The changing landscape of systemic therapy in metastatic renal cell carcinoma: an update.
    Gurram S; Al Harthy M; Ball MW
    Discov Med; 2020; 29(158):191-199. PubMed ID: 33007194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy.
    Rini BI; Campbell SC
    J Urol; 2007 Jun; 177(6):1978-84. PubMed ID: 17509276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role and timing of cytoreductive nephrectomy in the immunotherapy era.
    Wong ECL; Kapoor A
    Eur Urol Focus; 2020 Jan; 6(1):7-8. PubMed ID: 30824380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: How to Apply New Evidence in Clinical Practice.
    Soares A; Maia MC; Vidigal F; Marques Monteiro FS
    Oncology; 2020; 98(1):1-9. PubMed ID: 31514196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of pre-operative variables for identifying patients who might benefit from upfront cytoreductive nephrectomy for metastatic renal cell carcinoma in the targeted therapy era.
    You D; Jeong IG; Song C; Lee JL; Hong B; Hong JH; Ahn H; Kim CS
    Jpn J Clin Oncol; 2015 Jan; 45(1):96-102. PubMed ID: 25341544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic impact of systemic therapy change in metastatic renal cell carcinoma treated with cytoreductive nephrectomy.
    Ishihara H; Takagi T; Kondo T; Fukuda H; Tachibana H; Yoshida K; Iizuka J; Kobayashi H; Okumi M; Ishida H; Tanabe K
    Jpn J Clin Oncol; 2021 Feb; 51(2):296-304. PubMed ID: 32989464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.